All In Biotech

Drug Trial Radar · NCT02230566

A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7

Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12

Actual

Start

Dec 2014

Primary completion

May 2016

Study completion May 2016

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Sep 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 3 study will use a novel randomized, intra-subject placebo-controlled, single crossover design, referred to as Blind Start, to evaluate the safety and efficacy of UX003. The Blind Start is a novel design whereby participants will be randomized to 1 of 4 groups, each representing a different treatment sequence, and will cross over to UX003 at different pre-defined time points in a blinded manner. All groups will receive a minimum of 24 weeks treatment with 4 mg/kg UX003 every other week (QOW).

Conditions

  • MPS 7
  • Sly Syndrome
  • Mucopolysaccharidosis
  • MPS VII

Interventions

  • UX003Drug

    UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion

  • PlaceboOther

    Placebo consisting of the UX003 formulation buffer (without rhGUS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. European Union (EU) and Rest of World: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate (DS) at UX003 Treatment Week 24Time frame: Baseline (defined as the average of all assessments prior to or on the date of cross-over to active treatment with UX003) to 24 weeks of UX003 study drug treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Miami Children's Hospital

    Miami, Florida

  • University of Minnesota

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.